The therapeutic strategy for obesity-associated Mets and T2DM

The prevalence of obesity-associated adipose tissue inflammation with metabolic syndrome and T2DM are increasing. The current guidelines recommend the use of metformin-based combination therapy for patients with T2DM. The therapeutic strategy for obesity-associated metabolic syndrome and T2DM may require the inclusion of anti-inflammatory properties through appropriate drugs. We find an additional effect of metformin and celecoxib that represents a potential novel and powerful new strategy on obesity-associated lipid dysregulation and adipose tissue inflammation.